| Literature DB >> 29387271 |
Amit Rai1, Mohamed H Aboumanei2, Suraj P Verma3, Sachidanand Kumar4, Vinit Raj1.
Abstract
INTRODUCTION: Ebola Virus Disease (EVD) is caused by Ebola virus, which is often accompanied by fatal hemorrhagic fever upon infection in humans. This virus has caused the majority of deaths in human. There are no proper vaccinations and medications available for EVD. It is pivoting the attraction of scientist to develop the potent vaccination or novel lead to inhibit Ebola virus. METHODS & MATERIALS: In the present study, we developed 3D-QSAR and the pharmacophoric model from the previous reported potent compounds for the Ebola virus. RESULTS & DISCUSSION: Results & Discussion: The pharmacophoric model AAAP.116 was generated with better survival value and selectivity. Moreover, the 3D-QSAR model also showed the best r2 value 0.99 using PLS factor. Thereby, we found the higher F value, which demonstrated the statistical significance of both the models. Furthermore, homological modeling and molecular docking study were performed to analyze the affinity of the potent lead. This showed the best binding energy and bond formation with targeted protein.Entities:
Keywords: 3D-QSAR; Ebola virus; Homological modeling and Molecular docking; Pharmacophore; Pharmacophore models
Year: 2017 PMID: 29387271 PMCID: PMC5748831 DOI: 10.2174/1874104501711010127
Source DB: PubMed Journal: Open Med Chem J ISSN: 1874-1045
Show the chemical formulae and IC50 value towards Ebola virus.
| Sr. No. | Structures | IC50 | Log IC50 |
|---|---|---|---|
| > | 4 | 0.602 | |
| 30 | 1.477 | ||
| 64 | 1.806 | ||
| 4 | 0.602 | ||
| 2 | 0.301 | ||
| 17 | 1.230 | ||
| 9 | 0.954 | ||
| 54 | 1.732 | ||
| 125 | 2.096 |
Shown the activity threshold of 1,3,4-thiadiazole derivatives.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| 0.602 | active | 2.64 | 4 | 2.741 | |
| 1.477 | active | 2.6 | 4 | 4.514 | |
| 1.806 | active | 2.19 | 4 | 0.811 | |
| 0.602 | active | 2.92 | 4 | 1.024 | |
| 0.301 | active | 2.89 | 4 | 1.213 | |
| 1.23 | active | 3 | 4 | 1.024 | |
| 0.954 | active | 2.94 | 4 | 1.152 | |
| 1.732 | active | 2.24 | 4 | 6.249 | |
| 2.096 | active | 2.04 | 4 | 2.508 |
Score of different parameters of the pharmacophoric hypothesis.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| AAPR.51 | 3.557 | 0.78 | 0.961 | 0.816 | 1.608 | 9 | 1.018 | 1.23 |
| AAPR.38 | 3.557 | 0.78 | 0.961 | 0.816 | 1.608 | 9 | 1.018 | 1.23 |
| AAAP.116 | 3.512 | 0.75 | 0.958 | 0.804 | 1.481 | 9 | 1.018 | 1.23 |
| AAAP.142 | 3.512 | 0.75 | 0.958 | 0.804 | 1.481 | 9 | 1.018 | 1.23 |
| AAPR.6 | 3.498 | 0.77 | 0.942 | 0.791 | 1.589 | 9 | 1.045 | 1.23 |
| AAPR.16 | 3.498 | 0.77 | 0.942 | 0.791 | 1.589 | 9 | 1.045 | 1.23 |
| AAAP.67 | 3.491 | 0.77 | 0.94 | 0.782 | 1.466 | 9 | 1.045 | 1.23 |
| AAAP.77 | 3.491 | 0.77 | 0.94 | 0.782 | 1.466 | 9 | 1.045 | 1.23 |
| AAAP.79 | 3.489 | 0.77 | 0.935 | 0.782 | 1.467 | 9 | 1.25 | 0.954 |
| AAAP.69 | 3.489 | 0.77 | 0.935 | 0.782 | 1.467 | 9 | 1.25 | 0.954 |
| AADP.107 | 3.418 | 0.68 | 0.941 | 0.795 | 1.372 | 9 | 1.212 | 1.23 |
| ADPR.56 | 3.414 | 0.69 | 0.936 | 0.784 | 1.523 | 9 | 1.212 | 1.23 |
| AADP.98 | 3.414 | 0.75 | 0.894 | 0.765 | 1.366 | 9 | 1.277 | 0.954 |
| AADP.96 | 3.411 | 0.72 | 0.9 | 0.787 | 1.337 | 9 | 1.195 | 1.23 |
| AAAP.146 | 3.41 | 0.69 | 0.945 | 0.779 | 1.481 | 9 | 0.444 | 1.806 |
| AAAP.120 | 3.41 | 0.69 | 0.945 | 0.779 | 1.481 | 9 | 0.444 | 1.806 |
| AADP.129 | 3.41 | 0.7 | 0.927 | 0.785 | 1.427 | 9 | 1.518 | 1.23 |
| AADP.59 | 3.41 | 0.75 | 0.898 | 0.761 | 1.448 | 9 | 1.25 | 0.954 |
| ADPR.32 | 3.408 | 0.74 | 0.9 | 0.766 | 1.638 | 9 | 1.25 | 0.954 |
| ADPR.46 | 3.407 | 0.74 | 0.899 | 0.769 | 1.526 | 9 | 1.277 | 0.954 |
| ADPR.76 | 3.406 | 0.73 | 0.882 | 0.792 | 1.665 | 9 | 1.018 | 1.23 |
| ADPR.44 | 3.403 | 0.73 | 0.899 | 0.771 | 1.527 | 9 | 1.045 | 1.23 |
| AADP.108 | 3.403 | 0.71 | 0.907 | 0.781 | 1.354 | 9 | 1.418 | 0.602 |
| ADPR.71 | 3.398 | 0.7 | 0.922 | 0.772 | 1.609 | 9 | 1.018 | 1.23 |
| AADP.41 | 3.396 | 0.7 | 0.902 | 0.792 | 1.439 | 9 | 1.045 | 0.301 |
| AADP.133 | 3.392 | 0.68 | 0.927 | 0.783 | 1.431 | 9 | 1.018 | 0.954 |
| AADP.57 | 3.383 | 0.75 | 0.895 | 0.737 | 1.448 | 9 | 0.961 | 0.301 |
| ADPR.5 | 3.374 | 0.71 | 0.893 | 0.767 | 1.529 | 9 | 1.443 | 1.23 |
| ADPR.4 | 3.368 | 0.73 | 0.896 | 0.743 | 1.527 | 9 | 0.825 | 0.602 |
| AAAP.81 | 3.355 | 0.66 | 0.927 | 0.765 | 1.481 | 9 | 0.811 | 0.602 |
| AAAP.71 | 3.355 | 0.66 | 0.927 | 0.765 | 1.481 | 9 | 0.811 | 0.602 |
| AAPR.20 | 3.34 | 0.67 | 0.91 | 0.758 | 1.605 | 9 | 0.811 | 0.602 |
| ADPR.24 | 3.326 | 0.67 | 0.922 | 0.732 | 1.54 | 9 | 1.518 | 0.954 |
| ADPR.20 | 3.325 | 0.65 | 0.904 | 0.775 | 1.612 | 9 | 1.018 | 0.301 |
| AADP.51 | 3.319 | 0.66 | 0.923 | 0.733 | 1.388 | 9 | 1.045 | 0.954 |
| AAPR.7 | 3.223 | 0.63 | 0.937 | 0.659 | 1.587 | 9 | 4.668 | 0.602 |
| AAPR.17 | 3.223 | 0.63 | 0.937 | 0.659 | 1.587 | 9 | 4.668 | 0.602 |
| AAPR.33 | 3.174 | 0.63 | 0.86 | 0.685 | 1.593 | 9 | 3.576 | 1.477 |
| AAPR.30 | 3.174 | 0.63 | 0.86 | 0.685 | 1.593 | 9 | 3.576 | 1.477 |
| AAPR.12 | 3.082 | 0.66 | 0.823 | 0.595 | 1.592 | 9 | 5.757 | 1.732 |
Fitness, training set and activity data of predicted compounds.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| training | 0.602 | 1 | 0.71 | active | 2.64 | |
| training | 1.477 | 1 | 1.08 | active | 2.6 | |
| training | 1.806 | 1 | 1.91 | active | 2.19 | |
| training | 0.602 | 1 | 0.72 | active | 2.92 | |
| test | 0.301 | 1 | 0.93 | active | 2.89 | |
| test | 1.23 | 1 | 0.84 | active | 3 | |
| training | 0.954 | 1 | 1.02 | active | 2.94 | |
| test | 1.732 | 1 | 1.18 | active | 2.24 | |
| test | 2.096 | 1 | 1.09 | active | 2.04 |
PLS statistical parameters and 3D-QSAR models.
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| AAPR.51 | 1 | 0.2602 | 0.8245 | 14.1 | 0.03302 | -0.3794 | 0.6842 | -0.0307 | 0.6322 |
| AAPR.38 | 1 | 0.2602 | 0.8245 | 14.1 | 0.03302 | -0.3794 | 0.6842 | -0.0307 | 0.6322 |
| AAAP.116 | 1 | 0.2252 | 0.8686 | 19.8 | 0.02108 | -0.2082 | 0.6933 | -0.0583 | 0.5413 |
| AAAP.142 | 1 | 0.2252 | 0.8686 | 19.8 | 0.02108 | -0.2082 | 0.6933 | -0.0583 | 0.5413 |
| AAPR.6 | 1 | 0.1374 | 0.9511 | 58.3 | 0.004661 | -1.3301 | 0.788 | -0.367 | -0.0364 |
| AAPR.16 | 1 | 0.1374 | 0.9511 | 58.3 | 0.004661 | -1.3301 | 0.788 | -0.367 | -0.0364 |
| AAAP.67 | 1 | 0.1497 | 0.9419 | 48.6 | 0.006051 | -1.4557 | 0.8007 | -0.4116 | -0.1417 |
| AAAP.77 | 1 | 0.1497 | 0.9419 | 48.6 | 0.006051 | -1.4557 | 0.8007 | -0.4116 | -0.1417 |
| AAAP.79 | 1 | 0.1186 | 0.9635 | 79.3 | 0.002989 | -1.2491 | 0.7529 | -0.2481 | 0.4172 |
| AAAP.69 | 1 | 0.1186 | 0.9635 | 79.3 | 0.002989 | -1.2491 | 0.7529 | -0.2481 | 0.4172 |
| AADP.107 | 1 | 0.1627 | 0.9313 | 40.7 | 0.0078 | -0.2299 | 0.8464 | -0.5772 | 0.1245 |
| ADPR.56 | 1 | 0.2025 | 0.8937 | 25.2 | 0.01521 | -0.3227 | 0.8367 | -0.5415 | 0.2858 |
| AADP.98 | 1 | 0.1888 | 0.9076 | 29.5 | 0.01227 | -0.188 | 0.7304 | -0.1746 | 0.5767 |
| AADP.96 | 1 | 0.257 | 0.8288 | 14.5 | 0.03178 | -0.5437 | 0.5817 | 0.2551 | 0.6967 |
| AAAP.146 | 1 | 0.1588 | 0.9346 | 42.9 | 0.007243 | -0.5025 | 0.7252 | -0.1579 | 0.5628 |
| AAAP.120 | 1 | 0.1588 | 0.9346 | 42.9 | 0.007243 | -0.5025 | 0.7252 | -0.1579 | 0.5628 |
| AADP.129 | 1 | 0.1641 | 0.9301 | 39.9 | 0.008006 | 0.8099 | 0.7937 | -0.3871 | 0.4093 |
| AADP.59 | 1 | 0.2485 | 0.8399 | 15.7 | 0.02863 | -0.6287 | 0.6869 | -0.0387 | 0.5404 |
| ADPR.32 | 1 | 0.2487 | 0.8396 | 15.7 | 0.0287 | -0.5436 | 0.7129 | -0.1189 | 0.4502 |
| ADPR.46 | 1 | 0.1893 | 0.9071 | 29.3 | 0.01237 | -0.1546 | 0.725 | -0.1572 | 0.65 |
| ADPR.76 | 1 | 0.0632 | 0.9897 | 287.1 | 0.000448 | 0.4058 | 0.6192 | 0.1558 | 0.8282 |
| ADPR.44 | 1 | 0.2026 | 0.8936 | 25.2 | 0.01523 | -0.2396 | 0.7572 | -0.2625 | 0.2791 |
| AADP.108 | 1 | 0.1186 | 0.9635 | 79.2 | 0.002991 | -0.6686 | 0.7547 | -0.254 | 0.2485 |
| ADPR.71 | 1 | 0.1695 | 0.9255 | 37.3 | 0.008824 | 0.8089 | 0.7692 | -0.3026 | 0.5387 |
| AADP.41 | 1 | 0.3284 | 0.7203 | 7.7 | 0.069 | 0.33 | 0.8206 | -0.4824 | 0.6353 |
| AADP.133 | 1 | 0.1642 | 0.9301 | 39.9 | 0.008014 | 0.8164 | 0.8018 | -0.4153 | 0.3439 |
| AADP.57 | 1 | 0.2495 | 0.8386 | 15.6 | 0.02899 | -0.9388 | 0.6869 | -0.0387 | 0.5562 |
| ADPR.5 | 1 | 0.1735 | 0.9219 | 35.4 | 0.009484 | -0.4671 | 0.7597 | -0.2707 | 0.3427 |
| ADPR.4 | 1 | 0.2209 | 0.8735 | 20.7 | 0.01987 | -0.3611 | 0.7457 | -0.2243 | 0.3231 |
| AAAP.81 | 1 | 0.1374 | 0.9511 | 58.3 | 0.004665 | -0.0653 | 0.6862 | -0.0367 | 0.729 |
| AAAP.71 | 1 | 0.1374 | 0.9511 | 58.3 | 0.004665 | -0.0653 | 0.6862 | -0.0367 | 0.729 |
| AAPR.20 | 1 | 0.1739 | 0.9216 | 35.2 | 0.009554 | -0.1645 | 0.7131 | -0.1195 | 0.5763 |
| ADPR.24 | 1 | 0.1264 | 0.9586 | 69.4 | 0.003626 | -1.7048 | 0.717 | -0.1317 | 0.5283 |
| ADPR.20 | 1 | 0.341 | 0.6986 | 7 | 0.07786 | 0.3837 | 0.8475 | -0.5812 | 0.6044 |
| AADP.51 | 1 | 0.093 | 0.9776 | 130.7 | 0.001437 | -1.6832 | 0.7072 | -0.101 | 0.6132 |
| AAPR.7 | 1 | 0.3438 | 0.6935 | 6.8 | 0.08001 | 0.0111 | 0.634 | 0.115 | 0.7229 |
| AAPR.17 | 1 | 0.3438 | 0.6935 | 6.8 | 0.08001 | 0.0111 | 0.634 | 0.115 | 0.7229 |
| AAPR.33 | 1 | 0.375 | 0.6353 | 5.2 | 0.1063 | -0.0898 | 0.6637 | 0.0301 | 0.599 |
| AAPR.30 | 1 | 0.375 | 0.6353 | 5.2 | 0.1063 | -0.0898 | 0.6637 | 0.0301 | 0.599 |
| AAPR.12 | 1 | 0.1439 | 0.9463 | 52.9 | 0.005366 | 0.6401 | 0.7928 | -0.3837 | -0.2362 |
Docking affinity of titled compound with assigned VP40 (Zaire ebolavirus).
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| 5 | Ebola virus | -8.0 | PRO A 97 LEU A 98 GLY A 99 ARG A 148 GLN A 155 PHE A 157 LEU A 158 PHE A 161 LYS A 212 LEU A 213 ARG A 214 LEU A 288 PRO A 290 CYS A 314 HIS A 315 SER A 316 | 2 | 4 |